Text Size

Hospital Acquired and Community Acquired MRSA in GI Lab

This study has been withdrawn prior to enrollment.
(study lacked funding to recruit)
Sponsor:
Information provided by:
Indiana University
ClinicalTrials.gov Identifier:
NCT00577343
First received: December 19, 2007
Last updated: February 16, 2011
Last verified: February 2011
History of Changes
  Purpose

Hospital acquired and community acquired methicillin resistant staph aureus (MRSA) has become an important health issue for in recent years. Up to two thirds of patients that are hospitalized may be colonized with MRSA. The prevalence in the community is also on the rise and affects the young and healthy. It is unclear what the true prevalence of MRSA is in our own hospital and outpatient setting. This information would be relevant to how healthcare staff adhere to contact and universal precautions. : The purpose of this study is to determine the prevalence of MRSA in patients that have gastrointestinal endoscopy and endoscopic ultrasound.


Condition
Hospital Acquired MRSA
Community Acquired MRSA

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Hospital Acquired and Community Acquired Methicillin Resistant Staph Aureus in the Outpatient Gastrointestinal Lab: A Prospective Study of Prevalence

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Indiana University:

Primary Outcome Measures:
  • The objective of this prospective study is to identify the prevalence of MRSA in patients that use the Indiana University GI lab. [ Time Frame: less than one year ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples Without DNA

buccal swab for saliva


Estimated Enrollment: 1000
Study Start Date: April 2009
Estimated Study Completion Date: December 2010
Estimated Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years to 90 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

gastrointestinal lab of oupatient and inpatients

Criteria

Inclusion Criteria:

  • No evidence of dementia or altered mental status that would prohibit the giving and understanding of informed consent, and no evidence of psychiatric risk that would preclude adequate compliance with this protocol.

Subjects must provide signed written informed consent.

Exclusion Criteria:

  • Inability to provide written informed consent.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00577343

Locations
United States, Indiana
Clarian/Indiana University Hospital
Indianapolis, Indiana, United States, 46202
Sponsors and Collaborators
Indiana University
  More Information

No publications provided

Responsible Party: Dr. Julia LeBlanc, Indiana University
ClinicalTrials.gov Identifier: NCT00577343     History of Changes
Other Study ID Numbers: 0705-31
Study First Received: December 19, 2007
Last Updated: February 16, 2011
Health Authority: United States: Institutional Review Board

ClinicalTrials.gov processed this record on May 23, 2013